# NEOVADE (NCT06300424)

> Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06300424
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Guangdong Provincial People's Hospital
- Conditions: Non Small Cell Lung Cancer; EGFR Gene Mutation
- Interventions: almonertinib; Carboplatin; Nab paclitaxel
- Enrollment: 32
- Primary outcome: Major Pathological Response (MPR)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=neovade-nct06300424